Big Pharma is under the gun, with plenty of top management changes. By early next year, the industry will have seen five new CEOs; five new CFOs; a handful of changes in the top R&D spots, and a couple of new commercial bosses, all announced since the beginning of 2007 (an exhibit charts the changes). Of the sixteen job changes, six came about because the predecessor in the job was, if not outright fired, at least pressured to leave. But how much change are we really going to see?
With Big Pharma under the gun, changes in top management should be no surprise.
Still, the number of new faces is impressive (see Exhibit 1 for a review of what we think are the...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
